An experimental drug could help to improve movement for patients with spinal cord injuries. NVG-291, an injectable peptide, has been tested in a phase 2 trial with eligible patients — some of whom ...
An experimental gene therapy was found to slow the progression of Huntington’s disease in a “pivotal” Phase 1/2 study, according to drugmaker uniQure, marking a major step toward a potential first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback